BioSpace News Archive

Outlook Therapeutics, Inc. today announced that a 1-for-20 reverse stock split of its outstanding shares of common stock will be effective on March 14, 2024.

NewAmsterdam Pharma Company N.V. announced the dosing of the first patient and initiation of TANDEM, a pivotal Phase 3 clinical trial to evaluate obicetrapib and ezetimibe FDC in adult patients with Heterozygous Familial Hypercholesterolemia and/or Atherosclerotic Cardiovascular Disease or multiple risk factors for ASCVD, whose LDL-C is not adequately controlled despite being on maximally tolerated lipid-modifying therapies.

Aileron Therapeutics, Inc. today announced that current President and Chief Operating Officer, Brian Windsor, Ph.D., has been appointed President and Chief Executive Officer (CEO) and will join the Board of Directors, effective March 11, 2024.

Lexicon Pharmaceuticals, Inc. announced that a post hoc analysis of clinical data from its inTandem3 Phase 3 trial demonstrated that treatment with sotagliflozin resulted in improved glycemic control in patients with type 1 diabetes and chronic kidney disease.

NeuroGenesis Bio Inc. announced positive results from the interim analysis of the open-label extension period of a randomized, double-blind, placebo-controlled, Phase 2 clinical trial assessing the long-term effects of its lead asset, NG-01, on the two main serum biomarkers of MS activity and progression, on physical and cognitive assessments, and patient-reported outcomes in progressive MS.

Azenta, Inc. announced that Company management will participate in Virtual KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, which includes a presentation beginning at 12:45 pm ET.

Nutcracker Therapeutics, Inc. today announced that two poster presentations highlighting the company’s RNA therapeutics pipeline will be introduced at the 2024 American Association for Cancer Research (AACR) Annual Meeting.

Mainstay Medical Holdings plc announced the publication of a pooled analysis of three different clinical studies that evaluated the safety and efficacy of ReActiv8 therapy after two years in patients of various ages.

Provell Pharmaceuticals, a healthcare company that distributes world-class, branded drugs at generic prices by eliminating middlemen markups, announced a partnership with Mark Cuban Cost Plus Drug Company, PBC to offer patients direct access to a leading hypothyroid drug, Euthyrox®, at low-cost prices on the Cost Plus Drugs online platform.

Natera, Inc. today announced new data being presented on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, and hereditary cancer test, Empower™, at the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer taking place March 16-18, 2024.